A PLACEBO-CONTROLLED, DOUBLE-BLIND, PARALLEL-GROUP, 24 MONTH STUDY TO EVALUATE THE EFFICACY AND SAFETY OF E2609 IN SUBJECTS DIAGNOSED WITH EARLY ALZHEIMER'S DISEASE
Principal Investigator(s)
          Royall, Donald R
              Funded by
              EISAI INC.
          Research Start Date
              Status
              Active
          
